DK1183035T3 - BONE MARROW TRANSPLANT TREATMENT stroke - Google Patents
BONE MARROW TRANSPLANT TREATMENT stroke Download PDFInfo
- Publication number
- DK1183035T3 DK1183035T3 DK00935910T DK00935910T DK1183035T3 DK 1183035 T3 DK1183035 T3 DK 1183035T3 DK 00935910 T DK00935910 T DK 00935910T DK 00935910 T DK00935910 T DK 00935910T DK 1183035 T3 DK1183035 T3 DK 1183035T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- bone marrow
- mscs
- transplantation
- brain
- Prior art date
Links
- 210000001185 bone marrow Anatomy 0.000 title claims description 30
- 238000002054 transplantation Methods 0.000 claims description 44
- 210000004556 brain Anatomy 0.000 claims description 41
- 208000006011 Stroke Diseases 0.000 claims description 28
- 210000002569 neuron Anatomy 0.000 claims description 21
- 210000000130 stem cell Anatomy 0.000 claims description 11
- 210000003169 central nervous system Anatomy 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 96
- 241000700159 Rattus Species 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 49
- 241000699670 Mus sp. Species 0.000 description 29
- 208000014674 injury Diseases 0.000 description 29
- 230000006378 damage Effects 0.000 description 27
- 210000002798 bone marrow cell Anatomy 0.000 description 26
- 208000027418 Wounds and injury Diseases 0.000 description 25
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 24
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 22
- 229950004398 broxuridine Drugs 0.000 description 22
- 230000001537 neural effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 16
- 108010025020 Nerve Growth Factor Proteins 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 102000015336 Nerve Growth Factor Human genes 0.000 description 13
- 230000006872 improvement Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 229940053128 nerve growth factor Drugs 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 230000000302 ischemic effect Effects 0.000 description 12
- 208000020431 spinal cord injury Diseases 0.000 description 12
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 11
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 208000030886 Traumatic Brain injury Diseases 0.000 description 10
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 210000001577 neostriatum Anatomy 0.000 description 10
- 230000004770 neurodegeneration Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 9
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 9
- 238000010322 bone marrow transplantation Methods 0.000 description 9
- 210000001178 neural stem cell Anatomy 0.000 description 9
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 8
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 8
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 8
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000009529 traumatic brain injury Effects 0.000 description 8
- 241000700157 Rattus norvegicus Species 0.000 description 7
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 7
- 210000001130 astrocyte Anatomy 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000000926 neurological effect Effects 0.000 description 7
- 230000007658 neurological function Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 210000000278 spinal cord Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 210000004738 parenchymal cell Anatomy 0.000 description 6
- 238000009227 behaviour therapy Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 5
- 229960003132 halothane Drugs 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000007659 motor function Effects 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000003140 astrocytic effect Effects 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 230000009519 contusion Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- GFZPJHFJZGRWMQ-UHFFFAOYSA-M diOC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.O1C2=CC=CC=C2[N+](CCCCCCCCCCCCCCCCCC)=C1C=CC=C1N(CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2O1 GFZPJHFJZGRWMQ-UHFFFAOYSA-M 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000012137 double-staining Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 230000000508 neurotrophic effect Effects 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- 210000004129 prosencephalon Anatomy 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000003238 somatosensory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 238000001604 Rao's score test Methods 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 238000007428 craniotomy Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- -1 e.g. Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 210000000956 olfactory bulb Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000010825 rotarod performance test Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- LMGBDZJLZIPJPZ-UHFFFAOYSA-M 1-methyl-4-phenylpyridin-1-ium;chloride Chemical compound [Cl-].C1=C[N+](C)=CC=C1C1=CC=CC=C1 LMGBDZJLZIPJPZ-UHFFFAOYSA-M 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
- 101100231743 Homo sapiens HPRT1 gene Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 101000708422 Podarcis siculus Tissue- and phase-specific nuclear protein Proteins 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007470 bone biopsy Methods 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003059 ependyma Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000008043 neural expression Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000002475 olfactory pathway Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009478 tonic inhibition Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13434499P | 1999-05-14 | 1999-05-14 | |
| PCT/US2000/012875 WO2000069448A1 (en) | 1999-05-14 | 2000-05-11 | Bone marrow transplantation for treatment of stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1183035T3 true DK1183035T3 (en) | 2015-03-09 |
Family
ID=22462927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00935910T DK1183035T3 (en) | 1999-05-14 | 2000-05-11 | BONE MARROW TRANSPLANT TREATMENT stroke |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090162327A1 (https=) |
| EP (1) | EP1183035B1 (https=) |
| JP (1) | JP2002544234A (https=) |
| AU (1) | AU780994B2 (https=) |
| CA (1) | CA2373808C (https=) |
| DK (1) | DK1183035T3 (https=) |
| ES (1) | ES2531592T3 (https=) |
| PT (1) | PT1183035E (https=) |
| WO (1) | WO2000069448A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653134B2 (en) * | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| US20050169896A1 (en) * | 1999-05-14 | 2005-08-04 | Henry Ford Health System | Bone marrow transplantation for treatment of stroke |
| US8017112B2 (en) | 1999-05-14 | 2011-09-13 | Henry Ford Health System | Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases |
| IL148175A0 (en) * | 1999-08-18 | 2002-09-12 | Gen Hospital Corp | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| US6749850B1 (en) | 1999-08-18 | 2004-06-15 | The General Hospital Corporation | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| WO2001075094A1 (en) * | 2000-04-04 | 2001-10-11 | Thomas Jefferson University | Application of myeloid-origin cells to the nervous system |
| EP1302534A4 (en) | 2000-06-26 | 2004-06-16 | Renomedix Inst Inc | CELL FRACTION WITH CELLS WHICH ARE ABLE TO DIFFERENTIATE IN NERVOUS CELLS |
| ES2180433B1 (es) * | 2001-05-28 | 2004-05-16 | Universidad Miguel Hernandez De Elche. | Empleo de celulas madre hematopoyeticas en la generacion de celulas madre neurales. |
| US9969980B2 (en) | 2001-09-21 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
| WO2003038075A1 (en) * | 2001-10-30 | 2003-05-08 | Renomedix Institute Inc. | Method of inducing differentiation of mesodermal stem cells, es cells or immortalized cells into nervous system cells |
| EP1469852A4 (en) * | 2002-01-04 | 2009-12-02 | Ford Henry Health System | NITROGEN DONORS FOR THE TREATMENT OF DISEASE AND INJURY |
| AU2003202988A1 (en) | 2002-01-14 | 2003-07-30 | The Board Of Trustees Of The University Of Illinois | Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| US9969977B2 (en) | 2002-09-20 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
| WO2005007176A1 (ja) * | 2003-06-27 | 2005-01-27 | Renomedix Institute Inc. | 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬 |
| US20060210544A1 (en) | 2003-06-27 | 2006-09-21 | Renomedix Institute, Inc. | Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient |
| RU2283121C2 (ru) * | 2004-11-29 | 2006-09-10 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Способ лечения инсульта |
| US20080107632A1 (en) * | 2006-09-06 | 2008-05-08 | Henrich Cheng | Fibrin glue composition for repairing nerve damage and methods thereof |
| EP2171043B1 (en) | 2007-06-15 | 2015-03-18 | Garnet BioTherapeutics, Inc | Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro |
| JP5276816B2 (ja) * | 2007-09-10 | 2013-08-28 | 肇 井上 | 神経機能改善剤 |
| WO2009108632A1 (en) * | 2008-02-28 | 2009-09-03 | Henry Ford Health System | Compositions and methods for using stromal cells to enhance treatment of central nervous system injuries |
| EP2953473B1 (en) | 2013-02-06 | 2018-11-28 | Nc Medical Research Inc. | Method of producing a heterogeneous subpopulation of bone marrow cells suitable for the treatement of neurodegeneration cased by ischemic stroke |
| CA2926575C (en) * | 2013-10-14 | 2023-01-31 | Hadasit Medical Research Services & Development Limited | Method of obtaining terminally differentiated neuronal lineages and uses thereof |
| WO2015174087A1 (ja) * | 2014-05-16 | 2015-11-19 | 公益財団法人先端医療振興財団 | 脳梗塞の予防及び／又は治療の為の医薬 |
| RU2612981C1 (ru) * | 2015-12-21 | 2017-03-14 | Алексей Сергеевич Бывальцев | Способ лечения ишемического инсульта |
| US11464804B1 (en) | 2017-11-15 | 2022-10-11 | Enrico Stazzone | Intrathecal multifactorial infusion of heterogeneous autologous cell therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) * | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) * | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) * | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) * | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5612211A (en) * | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
| US5851832A (en) * | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
| US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| PT696205E (pt) * | 1993-04-13 | 2002-07-31 | Us Gov Health & Human Serv | Utilizacao de linhas celulares fetais nauro-derivadas para terapia de transplantacao |
| US6653134B2 (en) * | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| AU3888699A (en) * | 1998-05-07 | 1999-11-23 | University Of South Florida | Bone marrow cells as a source of neurons for brain and spinal cord repair |
| GB9904281D0 (en) * | 1999-02-24 | 1999-04-21 | Reneuron Ltd | Transplantation |
-
2000
- 2000-05-11 ES ES00935910.0T patent/ES2531592T3/es not_active Expired - Lifetime
- 2000-05-11 EP EP00935910.0A patent/EP1183035B1/en not_active Expired - Lifetime
- 2000-05-11 DK DK00935910T patent/DK1183035T3/en active
- 2000-05-11 AU AU51300/00A patent/AU780994B2/en not_active Ceased
- 2000-05-11 CA CA2373808A patent/CA2373808C/en not_active Expired - Fee Related
- 2000-05-11 JP JP2000617907A patent/JP2002544234A/ja active Pending
- 2000-05-11 WO PCT/US2000/012875 patent/WO2000069448A1/en not_active Ceased
- 2000-05-11 PT PT00935910T patent/PT1183035E/pt unknown
-
2008
- 2008-10-10 US US12/249,687 patent/US20090162327A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1183035B1 (en) | 2014-12-03 |
| CA2373808C (en) | 2011-04-19 |
| AU780994B2 (en) | 2005-04-28 |
| WO2000069448A1 (en) | 2000-11-23 |
| EP1183035A1 (en) | 2002-03-06 |
| CA2373808A1 (en) | 2000-11-23 |
| AU5130000A (en) | 2000-12-05 |
| US20090162327A1 (en) | 2009-06-25 |
| JP2002544234A (ja) | 2002-12-24 |
| ES2531592T3 (es) | 2015-03-17 |
| PT1183035E (pt) | 2015-03-04 |
| EP1183035A4 (en) | 2003-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1183035T3 (en) | BONE MARROW TRANSPLANT TREATMENT stroke | |
| US20240226174A1 (en) | Methods and compositions for provision of angiogenic factors | |
| US20050169896A1 (en) | Bone marrow transplantation for treatment of stroke | |
| RU2468818C2 (ru) | Способы, фармацевтические композиции и изделия для введения терапевтических клеток в центральную нервную систему животного | |
| US8940293B2 (en) | Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases | |
| RU2332223C2 (ru) | Материал стромальных клеток костного мозга для применения в формировании кровеносных сосудов и выработки факторов ангиогенеза и трофических факторов | |
| US6214334B1 (en) | Compositions and methods for producing and using homogenous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries | |
| US20080075698A1 (en) | Brain-Localizing Bone Marrow Progenitor cells | |
| US20220241345A1 (en) | Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke | |
| Matías-Guiu et al. | Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis | |
| US20080226609A1 (en) | Transplantation of Glial Restricted Precursor-Derived Astrocytes for Promotion of Axon Growth | |
| US6254865B1 (en) | Method of treating huntington's disease using HNT neurons | |
| Cho et al. | The behavioral effect of human mesenchymal stem cell transplantation in cold brain injured rats | |
| JP7762915B2 (ja) | 運動ニューロン疾患（ｍｎｄ）の治療に有効な多能性幹細胞 | |
| US7459152B2 (en) | Erythropoietin administration to improve graft survival | |
| US20040147020A1 (en) | Dopamine neurons from human embryonic stem cells | |
| Morris et al. | Neural Stem Cell Intervention in Traumatic Brain Injury | |
| Donsante et al. | Stem Cells for Amyotrophic Lateral Sclerosis | |
| Shulman et al. | Application of autologous peripheral blood mononuclear cells into the area of spinal cord injury in a subacute period: a pilot study in pigs | |
| Kobayashi et al. | Spinal Cellular Implants in Treatment of Neurodegenerative Disorders | |
| Costa et al. | The Power of Stem Cells and Neurotrophic Factors in the Quest for Alzheimer’s Disease Therapies | |
| Shah | Neuronal Differentiation of Cartilage-Derived Stem Cells In Vitro and their Delivery to the Spinal Cord in a Mouse Model of ALS Using MRI-guided Focused Ultrasound | |
| Dhib-Jalbut et al. | Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system | |
| WO2003018041A1 (en) | Method of treating spinal injury and remedy therefor | |
| LECTURE | Eleventh Annual Conference of the American Society for Neural Transplantation & Repair |